JP6676650B2 - 疾患を処置するためのコンジュゲート - Google Patents

疾患を処置するためのコンジュゲート Download PDF

Info

Publication number
JP6676650B2
JP6676650B2 JP2017548170A JP2017548170A JP6676650B2 JP 6676650 B2 JP6676650 B2 JP 6676650B2 JP 2017548170 A JP2017548170 A JP 2017548170A JP 2017548170 A JP2017548170 A JP 2017548170A JP 6676650 B2 JP6676650 B2 JP 6676650B2
Authority
JP
Japan
Prior art keywords
alkyl
alkenyl
alkynyl
cycloalkyl
aryl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2017548170A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018509424A (ja
JP2018509424A5 (enExample
Inventor
イオンチョ・ラドスラヴォフ・ヴラホフ
クリストファー・ポール・リーモン
ロンウー・チィ
インカイ・ワン
ケビン・ユー・ワン
ニン・ゾウ
アルバート・イー・フェルテン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Endocyte Inc
Original Assignee
Endocyte Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Endocyte Inc filed Critical Endocyte Inc
Publication of JP2018509424A publication Critical patent/JP2018509424A/ja
Publication of JP2018509424A5 publication Critical patent/JP2018509424A5/ja
Application granted granted Critical
Publication of JP6676650B2 publication Critical patent/JP6676650B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug
    • A61K47/551—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug one of the codrug's components being a vitamin, e.g. niacinamide, vitamin B3, cobalamin, vitamin B12, folate, vitamin A or retinoic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pyrrole Compounds (AREA)
  • Medicinal Preparation (AREA)
JP2017548170A 2015-03-13 2015-03-13 疾患を処置するためのコンジュゲート Active JP6676650B2 (ja)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US2015/020397 WO2016148674A1 (en) 2015-03-13 2015-03-13 Conjugates for treating diseases

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2020043256A Division JP2020117509A (ja) 2020-03-12 2020-03-12 疾患を処置するためのコンジュゲート

Publications (3)

Publication Number Publication Date
JP2018509424A JP2018509424A (ja) 2018-04-05
JP2018509424A5 JP2018509424A5 (enExample) 2018-05-24
JP6676650B2 true JP6676650B2 (ja) 2020-04-08

Family

ID=56920017

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2017548170A Active JP6676650B2 (ja) 2015-03-13 2015-03-13 疾患を処置するためのコンジュゲート

Country Status (6)

Country Link
US (2) US10624972B2 (enExample)
EP (1) EP3268046A4 (enExample)
JP (1) JP6676650B2 (enExample)
CN (1) CN107847609A (enExample)
CA (1) CA2979527A1 (enExample)
WO (1) WO2016148674A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3223860A4 (en) * 2014-11-25 2018-08-01 Endocyte, Inc. Methods of treating cancer by targeting tumor-associated macrophages
CN107847609A (zh) 2015-03-13 2018-03-27 恩多塞特公司 用于治疗疾病的缀合物
WO2017172930A1 (en) * 2016-03-29 2017-10-05 Endocyte, Inc. Pbd conjugates for treating diseases
CN109475558A (zh) * 2016-05-25 2019-03-15 普渡研究基金会 通过靶向骨髓衍生的抑制细胞而治疗癌症的方法
US11135307B2 (en) 2016-11-23 2021-10-05 Mersana Therapeutics, Inc. Peptide-containing linkers for antibody-drug conjugates
BR112022013008A2 (pt) 2019-12-31 2022-09-06 Legochem Biosciences Inc Composto derivado de pirrolobenzodiazepina, conjugado de derivado-ligante de pirrolobenzodiazepina, e, composição farmacêutica e método para prevenção ou tratamento de doença proliferativa

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS60255789A (ja) 1984-06-01 1985-12-17 Kyowa Hakko Kogyo Co Ltd マイトマイシン誘導体，その製造法および抗腫瘍剤
EP0457875A4 (en) 1989-11-13 1993-03-03 Xoma Corporation Chimeric mouse-human a10 antibody with specificity to a human tumor cell antigen
US5376645A (en) 1990-01-23 1994-12-27 University Of Kansas Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
KR0166088B1 (ko) 1990-01-23 1999-01-15 . 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도
EP0547163B1 (en) 1990-08-29 2002-02-06 Centre Hospitalier Regional De Nantes Protein polyligands joined to a stable protein core
AUPN449295A0 (en) * 1995-07-28 1995-08-24 Inner And Eastern Health Care Network, The Radioprotectors
GB9518953D0 (en) 1995-09-15 1995-11-15 Pfizer Ltd Pharmaceutical formulations
WO2000035298A1 (en) 1996-11-27 2000-06-22 Wm. Wrigley Jr. Company Chewing gum containing medicament active agents
GB9711643D0 (en) 1997-06-05 1997-07-30 Janssen Pharmaceutica Nv Glass thermoplastic systems
GB9818731D0 (en) 1998-08-27 1998-10-21 Univ Portsmouth Compounds
US6822086B1 (en) 1999-08-09 2004-11-23 The General Hospital Corporation Drug-carrier complexes and methods of use thereof
JP4813712B2 (ja) * 1999-08-09 2011-11-09 ザ ジェネラル ホスピタル コーポレーション 薬物−担体複合体およびその使用方法
US7601332B2 (en) 2003-01-27 2009-10-13 Endocyte, Inc. Vitamin receptor binding drug delivery conjugates
RU2470668C2 (ru) * 2005-08-19 2012-12-27 Эндосайт, Инк. Конъюгаты лиганда с несколькими лекарственными средствами
CN101287500A (zh) * 2005-08-19 2008-10-15 恩多塞特公司 多药物配体缀合物
JP2010518128A (ja) 2007-02-16 2010-05-27 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｃ型肝炎ｎｓ３プロテアーゼのインヒビター
BRPI0812970A2 (pt) * 2007-06-25 2019-09-24 Endocyte Inc conjugados contendo espaçadores hidrofílicos
JP5675619B2 (ja) 2008-09-17 2015-02-25 エンドサイト, インク.Endocyte, Inc. 葉酸拮抗薬の葉酸受容体結合性コンジュゲート
US20100074863A1 (en) * 2008-09-17 2010-03-25 Yat Sun Or Anti-infective pyrrolidine derivatives and analogs
PT2528625E (pt) * 2010-04-15 2013-10-17 Spirogen Sarl Pirrolobenzodiazepinas e conjugados das mesmas
RU2012154914A (ru) 2010-05-19 2014-06-27 Эндосайт, Инк. Улучшенный способ получения нацеленного на фолат средства
SI2675480T1 (sl) 2011-02-15 2019-05-31 Immunogen, Inc. Metode priprave konjugatov
CA2807712A1 (en) * 2012-03-01 2013-09-01 Purdue Research Foundation Methods for treating cancer
EA201590622A1 (ru) * 2012-10-16 2015-10-30 Эндосайт, Инк. Конъюгаты для доставки лекарственного средства, содержащие не встречающиеся в природе аминокислоты, и способы применения
KR102318999B1 (ko) * 2012-11-15 2021-10-29 엔도사이트, 인코포레이티드 Psma 발현 세포에 의해 야기되는 질병을 치료하기 위한 컨쥬게이트
US10131682B2 (en) * 2012-11-24 2018-11-20 Hangzhou Dac Biotech Co., Ltd. Hydrophilic linkers and their uses for conjugation of drugs to a cell binding molecules
US9567340B2 (en) 2012-12-21 2017-02-14 Medimmune Limited Unsymmetrical pyrrolobenzodiazepines-dimers for use in the treatment of proliferative and autoimmune diseases
SI3191135T1 (sl) 2014-09-12 2021-01-29 Genentech, Inc. Anti-HER2 protitelesa in imunokonjugati
EP3223860A4 (en) 2014-11-25 2018-08-01 Endocyte, Inc. Methods of treating cancer by targeting tumor-associated macrophages
CN107847609A (zh) 2015-03-13 2018-03-27 恩多塞特公司 用于治疗疾病的缀合物
WO2017172930A1 (en) 2016-03-29 2017-10-05 Endocyte, Inc. Pbd conjugates for treating diseases

Also Published As

Publication number Publication date
WO2016148674A1 (en) 2016-09-22
US10624972B2 (en) 2020-04-21
EP3268046A1 (en) 2018-01-17
EP3268046A4 (en) 2018-11-21
JP2018509424A (ja) 2018-04-05
CN107847609A (zh) 2018-03-27
US20200289659A1 (en) 2020-09-17
CA2979527A1 (en) 2016-09-22
US20180228914A1 (en) 2018-08-16

Similar Documents

Publication Publication Date Title
JP7195402B2 (ja) シリコン系薬物複合体及びその使用方法
US20200289659A1 (en) Conjugates for treating diseases
AU2014318826B2 (en) Targeted therapeutics
ES2755101T3 (es) Nuevos compuestos y conjugados de criptoficina, su preparación y su uso terapéutico
US20200323991A1 (en) Pbd conjugates for treating diseases
EP2836494B1 (en) New alkylating agents
US20180110871A1 (en) Dual disulfide drug conjugates
RU2632199C2 (ru) Функционализированные производные тиеноиндола для лечения ракового заболевания
WO2016089879A1 (en) Conjugates of garftase inhibitors
US10500286B2 (en) CCK2R-drug conjugates
JP2021006550A (ja) 炎症の治療のための抗葉酸剤結合体
US20160303251A1 (en) Conjugates of garftase inhibitors
US20180125992A1 (en) Drug delivery conjugates of tertiary amine containing drugs
JP2020117509A (ja) 疾患を処置するためのコンジュゲート
CA2720516C (en) Indoline anti-cancer agents
EP3049420B1 (en) Thieno[2,3-e]indole derivatives as new antitumor agents
BR112018008490B1 (pt) Compostos e conjugados de criptoficina, processos para a preparação dos mesmos, medicamento e composição farmacêutica

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20180312

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180322

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20181018

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20181023

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190122

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20190528

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190816

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20191015

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200114

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20200212

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20200312

R150 Certificate of patent or registration of utility model

Ref document number: 6676650

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250